Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmacyclics Inc PCYC

Healthcare Biotechnology

Recent & Breaking News (NDAQ:PCYC)

Supplemental New Drug Application for IMBRUVICA® Accepted by the U.S. FDA and Priority Review Granted

PR Newswire June 9, 2014

IMBRUVICA® (ibrutinib) Significantly Improves Progression Free Survival, Overall Survival and Overall Response as compared to Ofatumumab in Patients with Previously Treated CLL/SLL in its First Phase III study

PR Newswire May 31, 2014

IMBRUVICA® (ibrutinib) Shows Durable, Long-Term Responses for Patients with CLL

PR Newswire May 31, 2014

IMBRUVICA® (ibrutinib) Combination with anti CD20 Antibody Shows Compelling Results in Heavily Pretreated Patients with CLL and Related Diseases

PR Newswire May 31, 2014

Pharmacyclics appoints Gregory R. Wade to lead Business Development

PR Newswire May 20, 2014

Pharmacyclics Highlights Important New Data for IMBRUVICA® (ibrutinib) in B-Cell Malignancies

PR Newswire May 14, 2014

Pharmacyclics Reports First Quarter 2014 Results

PR Newswire May 2, 2014

Pharmacyclics Announces Date of Conference call to discuss Financial Results for First Quarter of 2014

PR Newswire April 25, 2014

Pharmacyclics Announces Presentation of Phase III and Long Term Follow Up Data on IMBRUVICA(TM) in Chronic Lymphocytic Leukemia (CLL) at ASCO

PR Newswire April 21, 2014

Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data

PR Newswire April 8, 2014

King: How the Oncology Drug Development Machine Builds Biotech Wealth

Equities.com March 17, 2014

BioClinica Technology Supports Pharmacyclics in Achieving Early Approval of IMBRUVICA(TM) and Breakthrough Therapy Designations for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)

PR Newswire March 11, 2014

Pharmacyclics Reports Fourth Quarter and Full Year 2013 Results

PR Newswire February 20, 2014

Pharmacyclics Announces Date of Conference call to discuss Financial Results for Fourth Quarter and Year End 2013

PR Newswire February 14, 2014

U.S. Food and Drug Administration Approves IMBRUVICA(TM) (ibrutinib) as a Single Agent for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy

PR Newswire February 12, 2014

Independent Data Monitoring Committee recommends Phase III study of IMBRUVICA(TM) (ibrutinib) versus ofatumumab be stopped early based on statistically significant improvement in progression free survival and overall survival

PR Newswire January 7, 2014

Versartis Appoints Joshua T. Brumm as Chief Financial Officer

Marketwired December 16, 2013

Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies

PR Newswire December 10, 2013

Ibrutinib Frontline Chronic Lymphocytic Leukemia Study Results Published in The Lancet Oncology

PR Newswire December 9, 2013

WuXi PharmaTech to Partner with Pharmacyclics

PR Newswire November 15, 2013